Yuval Cohen - Corbus Pharmaceuticals CEO and Director
| CRBP Stock | USD 17.47 0.74 4.42% |
CEO
Dr. Yuval Cohen, Ph.D., Chief Executive Officer and Director of the Company., since March 27, 2014. Dr. Cohen has served as our Chief Executive Officer and as a director since April 11, 2014. Dr. Cohen joined Corbus Pharmaceuticals, Inc., our whollyowned subsidiary, as its Chief Executive Officer in July 2013. Prior to joining Corbus Pharmaceuticals, Inc., he was the President and cofounder of Celsus Therapeutics PLC from 2005 until February 2013, and as Senior Vice President from February 2013 until June 2013. Dr. Cohen was also a board member of Celsus until December 2013. Starting as a small startup with seed financing, under Dr. Cohens leadership, Celsus developed five novel antiinflammatory drug candidates with two reaching Phase IIb stages focusing on allergies and autoimmune diseases of the skin, airways, digestive tract and eye . Dr. Cohen participated in all stages of the preclinical and clinical development from project management to interactions with regulatory bodies and with the investment community in fundraising. Apart from his industry experience, he is also the author of a number of peerreviewed papers and reviews as well as listed inventor on a number of patents. Dr. Cohen holds a BSc in microbiology and biochemistry from University of Cape Town, South Africa, and has a Ph.D., summa cum laude, from the Curie Institute of Cancer Research in Paris and the University of Paris V. Dr. Cohen was selected as a director because of his business and leadership experience in the biopharmaceutical sector, as well as a result of having served as a director since our inception.
| Age | 49 |
| Professional Marks | Ph.D |
| Address | 500 River Ridge Drive, Norwood, MA, United States, 02062 |
| Phone | 617 963 0100 |
| Web | https://www.corbuspharma.com |
Latest Insider Transactions
Cohen holds a KS. in microbiology and biochemistry from University of Cape Town, South Africa, and has a Ph.D., summa cum laude, from the Curie Institute of Cancer Research in Paris and the University of Paris V.Yuval Cohen Latest Insider Activity
Tracking and analyzing the buying and selling activities of Yuval Cohen against Corbus Pharmaceuticals stock is an integral part of due diligence when investing in Corbus Pharmaceuticals. Yuval Cohen insider activity provides valuable insight into whether Corbus Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Corbus Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Corbus Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Yuval Cohen over two months ago Disposition of 1770 shares by Yuval Cohen of Corbus Pharmaceuticals at 14.1 subject to Rule 16b-3 | ||
Yuval Cohen over three months ago Disposition of 2322 shares by Yuval Cohen of Corbus Pharmaceuticals at 42.237 subject to Rule 16b-3 |
Corbus Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.2882) % which means that it has lost $0.2882 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5132) %, meaning that it created substantial loss on money invested by shareholders. Corbus Pharmaceuticals' management efficiency ratios could be used to measure how well Corbus Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Corbus Pharmaceuticals' Return On Capital Employed is relatively stable compared to the past year. As of 11/25/2024, Return On Equity is likely to grow to 6.78, while Return On Tangible Assets are likely to drop (1.66). As of 11/25/2024, Liabilities And Stockholders Equity is likely to grow to about 50.5 M, while Total Current Liabilities is likely to drop slightly above 16.9 M.Similar Executives
| Found 10 records | CEO Age | ||
| Paula Ragan | X4 Pharmaceuticals | 54 | |
| Jeremy MBA | Day One Biopharmaceuticals | 53 | |
| Allen Baharaff | Galmed Pharmaceuticals | 59 | |
| Denise ScotsKnight | Mereo BioPharma Group | 65 | |
| Jason Okazaki | Assembly Biosciences | 48 | |
| Elizabeth MBA | Ocean Biomedical | 67 | |
| MSc JD | Cue Biopharma | 63 | |
| Adi Hoess | Affimed NV | 63 | |
| Daniel MBA | Acumen Pharmaceuticals | 54 | |
| Laurent Fischer | Adverum Biotechnologies | 60 | |
Management Performance
| Return On Equity | -0.51 | ||||
| Return On Asset | -0.29 |
Corbus Pharmaceuticals Leadership Team
Elected by the shareholders, the Corbus Pharmaceuticals' board of directors comprises two types of representatives: Corbus Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Corbus. The board's role is to monitor Corbus Pharmaceuticals' management team and ensure that shareholders' interests are well served. Corbus Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Corbus Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| MD MA, Chief Officer | ||
| Christina Bertsch, Head Resources | ||
| Ted Jenkins, Senior Director, Investor Relations and Communications | ||
| CPA MBA, Chief Officer | ||
| Rachael Brake, Chief Officer | ||
| Lindsey Smith, Head Advocacy | ||
| Yuval Cohen, CEO and Director | ||
| Scott Constantine, Director Operations | ||
| Craig MBA, Chief Officer |
Corbus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Corbus Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.51 | ||||
| Return On Asset | -0.29 | ||||
| Current Valuation | 57.02 M | ||||
| Shares Outstanding | 12.18 M | ||||
| Shares Owned By Insiders | 0.70 % | ||||
| Shares Owned By Institutions | 99.30 % | ||||
| Number Of Shares Shorted | 2.38 M | ||||
| Price To Earning | (8.87) X | ||||
| Price To Book | 1.41 X | ||||
| Price To Sales | 163.32 X |
Pair Trading with Corbus Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Corbus Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Corbus Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Corbus Stock
Moving against Corbus Stock
The ability to find closely correlated positions to Corbus Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Corbus Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Corbus Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Corbus Pharmaceuticals Holding to buy it.
The correlation of Corbus Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Corbus Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Corbus Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Corbus Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Corbus Stock Analysis
When running Corbus Pharmaceuticals' price analysis, check to measure Corbus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corbus Pharmaceuticals is operating at the current time. Most of Corbus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Corbus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corbus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Corbus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.